An observational study in Neovascular Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Active, not recruiting at 59 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Hoffmann-La Roche · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the only one that started in 2025, is one of 3 observational ones, and was the 23rd registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 14 · Phase 4 2
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 875 is above the median of 71 across 127 observational studies indexed under Macular Edema.
Median enrollment 377 across the 25 interventional studies, 736 across the 3 observational. Of the 23 that completed or were terminated, 17 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Macular Edema by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
| NCT06680817Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The FaReal study aims to evaluate the effectiveness, safety, clinical insights and treatment patterns in patients treated with faricimab, in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in at least one eye, in real-world routine clinical practice over a 2-year patient follow-up period. Additionally, the FaReal study also aims to describe and evaluate health economic aspects of previous anti-VEGF treatments and current treatment with faricimab.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
This study's planned enrollment of 875 is above the median of 71 across 127 observational studies indexed under Macular Edema.
Browse Macular Edema studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients being treated with faricimab approved for nAMD and DME in real-world, routine clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort will be divided into two sub-cohorts based on eye treatment history: anti-VEGF treatment naive and anti-VEGF pre-treated.
Drug: Faricimab
This cohort will be divided into two sub-cohorts based on eye treatment history: anti-VEGF treatment naive and anti-VEGF pre-treated.
Drug: Faricimab
Faricimab will be administered as per local clinical practice and local labeling.
Also known as: VABYSMO®, RO6867461, RG7716
Change in Visual Acuity from Index Date to 12 Months
The index date is defined as the date of the first faricimab treatment injection in the eye.
Time frame: Index Date and 12 months
Change in Visual Acuity from Index Date to 3, 6, and 24 Months
Time frame: Index Date and 3, 6, and 24 months
Change in Central Subfield Thickness (CST) from Index Date to 3, 6, 12, and 24 Months
Time frame: Index Date and 3, 6, 12, and 24 months
Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time
Time frame: Index Date and 3, 6, 12, and 24 months
Number of Faricimab Intravitreal Injections per Eye per Year
Time frame: 12 and 24 months
Number of Faricimab Intravitreal Injections in the Loading Phase for Participants who are anti-VEGF Treatment Naive or anti-VEGF pre-Treated
Time frame: Approximately 4 months
Total Number of Visits and Number of Visits With or Without Treatment Over Time
Time frame: 3, 6, 12, and 24 months
Cumulative Time Spent in Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other)
Time frame: From Index Date to 24 months
Percentage of Eyes With Treatment Switch from Faricimab by Reason for Switch in Participants who are anti-VEGF Treatment Naive or anti-VEGF pre-Treated
Time frame: 3, 6, 12, and 24 months
Percentage of Eyes Obtaining Treatment Intervals of Once Every 8, 12, or 16 Weeks or Other Intervals in Participants who are anti-VEGF Treatment Naive or anti-VEGF pre-Treated
Time frame: 12 and 24 months
Change in Visual Acuity from Index Date Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other)
Time frame: Index Date and 3, 6, 12, and 24 months
Change in Visual Acuity from Index Date Over Time, According to Number of Intravitreal Treatments
Time frame: Index Date and 3, 6, 12, and 24 months
Change in Visual Acuity from Index Date Over Time, According to Total Number of Visits
Time frame: Index Date and 3, 6, 12, and 24 months
Change in Visual Acuity from Index Date Over Time, According to Treatment Intervals
Time frame: Index Date and 3, 6, 12, and 24 months
Change in Visual Acuity from Index Date Over Time, According to Type of anti-VEGF Pre-Treatment and Number of Previous Injections for Preceding Regimen at Index Date
Time frame: Index Date and 3, 6, 12, and 24 months
Change in Visual Acuity from Index Date Over Time, According to Length of Diagnosis of Disease at Index Date
Time frame: Index Date and 3, 6, 12, and 24 months
Number of Participants with at Least One Ocular Adverse Event
Time frame: Approximately 2 years
Number of Participants with at Least One Non-Ocular Adverse Event
Time frame: Approximately 2 years
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.
Of 44 observational studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 28 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.